This article will review the current alternative strategies in the management of primary breast cancer with an emphasis on the reasons we prefer a particular strategy. We will attempt to forecast new alternatives that we expect to emerge from advances in the molecular biology of breast cancer, as well as other technological advances.
No takes yet. Share an insight, caveat, or question.
Roger S. Foster (1998) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: